Welcome to our dedicated page for Singular Genomics Systems news (Ticker: OMIC), a resource for investors and traders seeking the latest updates and insights on Singular Genomics Systems stock.
This page provides a historical news archive for Singular Genomics Systems, Inc., which previously traded on Nasdaq under the symbol OMIC. The company describes itself as a life science technology company developing next-generation sequencing (NGS) and multiomics technologies, including the G4® Sequencing Platform and the G4X™ Spatial Sequencer. Its news releases document product milestones, spatial biology data presentations, corporate transactions and capital markets developments.
Readers can review announcements about the G4 Sequencing Platform, which Singular Genomics characterizes as a powerful, highly versatile benchtop genomic sequencer designed to produce fast and accurate results. News items also cover progress on the G4X Spatial Sequencer, described as a system under development that will apply the company’s proprietary sequencing technology as an in situ readout for transcriptomics, proteomics and fluorescent H&E in tissue with spatial context.
The archive includes updates on spatial multiomics performance in FFPE tissues, 3D multi-omic reconstruction, Direct-Seq demonstrations for T- and B-cell receptor sequencing in tissue, and the company’s Spatial Technology Access Services program. In addition, corporate news covers events such as a 1-for-30 reverse stock split to address Nasdaq’s minimum bid price requirement, the receipt of acquisition proposals, the definitive merger agreement with an affiliate of Deerfield Management Company, L.P., and the closing of the Deerfield acquisition after stockholder approval.
Because Singular Genomics has stated that it now operates as a private company and has requested delisting from Nasdaq, the OMIC news feed serves as a record of its public-company history, technology development updates and key strategic decisions during its time as a listed issuer.
Singular Genomics Systems, Inc. (Nasdaq: OMIC) reported significant advancements and financial results for Q2 2022, highlighting the shipment of the first G4 production system in June 2022. The G4 offers superior power and accuracy for researchers. Operating expenses rose to $24.2 million, primarily due to R&D and workforce expansion, compared to $13.9 million in Q2 2021. However, the net loss decreased to $24 million ($0.34 per share) from $37.5 million ($1.18 per share) year-over-year. The company holds $287.5 million in cash and equivalents as of June 30, 2022, ensuring liquidity for growth initiatives.
Singular Genomics Systems (Nasdaq: OMIC) has announced a rescheduled time for its fireside chat at the UBS Genomics 2.0 and MedTech Innovations Summit. The event will now take place at 8:00 a.m. PT on August 11, 2022. Interested parties can listen to the live and recorded webcast at their investor relations website. Singular Genomics focuses on developing next-generation sequencing and multiomics technologies, with its G4 Sequencing Platform already available and a new PX system in development.
Singular Genomics Systems (Nasdaq: OMIC) announced the appointment of Sam Ropp, Ph.D., as Chief Commercial Officer and Jeff Bullard as Head of Sales for North America. Dr. Ropp will lead the commercial function for the G4 Sequencing Platform, enhancing the company's executive strength. His prior experience includes senior roles at 10x Genomics and Becton, Dickinson and Company. Jeff Bullard, also from 10x Genomics, brings extensive sales leadership experience. These strategic appointments aim to position Singular Genomics as a leader in next-generation sequencing technology.
Singular Genomics Systems, Inc. (Nasdaq: OMIC) will present at the UBS Genomics 2.0 and MedTech Innovations Summit on August 11, 2022, in Laguna Beach, California. The company's management will participate in a fireside chat scheduled for 1:00 p.m. PT / 4:00 p.m. ET. Investors can access a live and recorded webcast of the event on the company's investor site. Singular Genomics focuses on advanced next-generation sequencing and multiomics technologies, featuring its G4 Sequencing Platform and the upcoming PX system aimed at single-cell analysis.
Singular Genomics Systems is set to release its Q2 2022 financial results on August 9, 2022, after market close. The management will host a conference call at 1:30 p.m. Pacific Time to discuss the results. Investors can access the live and archived webcast through the company's investor relations site.
Singular Genomics develops next-generation sequencing and multiomics technologies, with its G4 Sequencing Platform already on the market and another system, PX, in development.
Olink and Singular Genomics announced a collaboration to integrate Olink's high-throughput proteomics platform with Singular's G4 Sequencing Platform using Max Read kits. This partnership aims to enhance proteomics research, offering up to 4 billion reads per run, thus improving cost-effectiveness and throughput. Executives from both companies highlight the potential for expanded customer options in sequencing technologies. This collaboration continues Olink's strategy to broaden its offerings since 2020.
Singular Genomics Systems Inc. (Nasdaq: OMIC) and TwinStrand Biosciences have announced a strategic partnership to enhance next-generation sequencing (NGS) technologies, particularly for detecting measurable residual disease (MRD) in oncology.
This collaboration combines TwinStrand’s Duplex Sequencing with Singular’s HD-Seq™ technology on the G4 Sequencing Platform, aiming to improve mutation detection sensitivity.
The partnership targets reduced sequencing costs, quicker turnaround times, and higher accuracy, potentially leading to a significant impact in cancer treatment and monitoring.
Singular Genomics Systems (Nasdaq: OMIC) announced plans to present at the Goldman Sachs 43rd Annual Global Healthcare Conference on June 14, 2022, at 4:00 p.m. PT. Management will participate in a fireside chat, which will be available via live and recorded webcast on the company's investor relations website.
Singular Genomics specializes in next-generation sequencing (NGS) and multiomics technologies, aiming to enhance genomic research and clinical applications. Their products include the G4 for NGS and the PX for integrated multiomics analysis.
Singular Genomics Systems, Inc. (Nasdaq: OMIC) reported financial results for Q1 2022, highlighting significant operational advancements. The company is on track to ship its G4 instruments and F2 flow cell kits in Q2 2022, bolstered by robust validation from its Beta and Early Access Program. Financially, operating expenses rose to $22.0 million due to headcount growth and investments in the G4 launch. The net loss was $22.0 million, or $0.31 per share, improved from a loss of $23.9 million in Q1 2021. Cash reserves stand at $316.0 million as of March 31, 2022.
Singular Genomics Systems (Nasdaq: OMIC) has announced a collaboration with NVIDIA to enhance the performance of its G4 Sequencing Platform using NVIDIA Clara Parabricks for secondary analysis. This partnership aims to optimize bioinformatics workflows for applications such as whole genome sequencing and RNA sequencing, enabling accelerated results for researchers. Users can access this solution through Amazon Web Services Cloud or on-premises with NVIDIA GPUs. The collaboration is expected to reduce time to results, thereby enhancing scientific and medical research capabilities.
FAQ
What is the current stock price of Singular Genomics Systems (OMIC)?
What is the market cap of Singular Genomics Systems (OMIC)?
